key: cord-0885925-jpr97wad
authors: Fragoso-Saavedra, S.; Nunez, I.; Audelo-Cruz, B. M.; Arias-Martinez, S.; Manzur-Sandoval, D.; Quintero-Villegas, A.; Garcia-Gonzalez, H. B.; Carbajal-Morelos, S. L.; Ponce de Leon-Rosales, S.; Gotes-Palazuelos, J.; Caro-Vega, Y.; Maza-Larrea, J.; Batina, I.; Islas-Weinstein, L.; Calva, J. J.; Iruegas-Nunez, D. A.; Belaunzaran-Zamudio, P. F.; Sierra-Madero, J.; Crispin, J. C.; Valdes-Ferrer, S. I.
title: Pyridostigmine in adults with severe SARS-CoV-2 infection: the PISCO trial
date: 2021-04-29
journal: nan
DOI: 10.1101/2021.04.28.21255834
sha: 597ee673fc006f046f6c89ac5f21bca37c3648c8
doc_id: 885925
cord_uid: jpr97wad

Background: Hospitalized patients with severe COVID-19 have an increased risk of developing severe systemic inflammatory response, pulmonary damage, and acute respiratory distress syndrome (ARDS), resulting in end-organ damage and death. Acetylcholine modulates the acute inflammatory response through a neuro-immune mechanism known as the inflammatory reflex. Pyridostigmine, an acetylcholine-esterase inhibitor, increases the half-life of endogenous ACh, chemically stimulating the inflammatory reflex. This trial aimed to evaluate whether pyridostigmine could decrease invasive mechanical ventilation (IMV) and death in patients with severe COVID-19. Methods: We performed a parallel-group, multicenter, double-blinded, placebo-controlled, randomized clinical trial to evaluate if add-on pyridostigmine to standard treatment reduced the composite outcome of initiation of IMV and 28-day all-cause mortality among hospitalized patients with severe COVID-19. Results: 188 participants were randomly assigned to placebo (n=94) or pyridostigmine (n=94). The composite outcome occurred in 22 (23.4%) vs. 11 (11.7%) participants, respectively (hazard ratio 0.46, 95% confidence interval 0.22-0.96, p=0.03). Most of the adverse events were mild to moderate, with no serious adverse events related to pyridostigmine; discontinuation of the study drugs was similar in both groups. Conclusions: We provide evidence indicating that the addition of pyridostigmine to standard treatment resulted in a clinically significant reduction in the composite outcome (IMV/death) among patients hospitalized for severe COVID-19. (Funded by Consejo Nacional de Ciencia y Tecnologia, Mexico; ClinicalTrials.gov number: NCT04343963).

, Mexico City, Mexico. Phone: 27 +52(55)5487-0900, ext. 4177. Email: sergio.valdesf@incmnsz.mx 28 29 All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 29, 2021. ; https://doi.org/10.1101/2021.04.28.21255834 doi: medRxiv preprint

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of coronavirus 53 disease 2019 (COVID-19) 1 ,may lead to severe systemic inflammatory response 2 , acute respiratory 54 distress syndrome 3 , multiple-organ failure, resulting and death 4,5 . 55

Among several drugs evaluated in clinical trials to mitigate COVID-19 severity, dexamethasone has 56 been shown to reduced mortality among patients requiring supplementary oxygen. However, its use is 57 accompanied by frequent adverse effects such as hyperglycemia, psychosis, and gastrointestinal 58 hemorrhage 6 . Remdesivir, an antiviral, alone or in combination with baricitinib, a selective inhibitor of 59 Janus kinases 1 and 2, accelerated recovery and reduced in-hospital stay, without a significant effect 60 on mortality 7,8 . Hence, therapeutic interventions able to ameliorate the morbidity and mortality caused 61 by SARS-CoV2 are urgently needed. 62

The central nervous system regulates the inflammatory response via the release of acetylcholine by 63 were allocated (1:1 ratio) to receive, in addition to standard medical treatment, either oral 78 pyridostigmine at a dose of 60 mg/day P.O. or a matching placebo (pharmaceutical-grade starch) until 79 the occurrence of any of the prespecified outcomes, hospital discharge, or 14 in-hospital days. The 80 primary outcome was a composite of invasive mechanical ventilation (IMV) or death in the 28 days 81 following randomization (Fig. 1) . Secondary outcomes were not prespecified and included: (a) the 82 length of in-hospital days after randomization; (b) hospital discharge by day-28; (c) among those who 83 required IMV, the number of days with, and the survival rate after IMV; (d) failure to complete 84 treatment as expected due to adverse events (other than the primary composite outcome). 85

Adverse events (AEs) were collected using data obtained from the medical health records of each 86 study participant. The events were evaluated and coded using the Medical Dictionary and Regulatory 87 Activities (MedDRA) version 24.0 browser and the severity of the AEs was assessed by the National 88

Cancer Institute Common Terminology Criteria for Adverse Events, version 5.0. 89

Although not used throughout the study, unblinding was allowed in case of severe adverse events at 90 the request of either the treating group of physicians or the external Data and Safety Monitoring Board 91 (DSMB). The study was conducted in two parts, as already described 17 : a phase 2 aimed at 92 determining safety (May 5 to July 4, 2020), followed by a phase 3 aimed at evaluating the effect -or 93 lack thereof-of pyridostigmine in patients with severe COVID-19 (July 5, 2020, to January 30, 2021 The trial was planned and approved in March 2020; funding was obtained in April 2020, shortly after 113 the first case of COVID-19 was diagnosed in Mexico. At that time, we relied on limited information 114 about clinical outcomes in these patients. Thus, we calculated a sample size of 436 participants 115 considering an event rate of 25% in the control group, considering a 10% absolute reduction (40% 116 relative reduction) in the primary outcome as clinically significant, and 80% power to detect a 117 difference in the primary outcome using a two-sided significance level of α =0.05 17 . However, the 118 sample size would be adjusted according to interim analyses. The first participant was recruited on to an observed difference in the primary outcome between groups (still blinded to investigators, but 123 unblinded to the DSMB), as well as difficulty recruiting new participants due to a reduction in eligible 124 patients and a swell in competing studies, we decided to stop the trial after 188 participants had been 125 recruited (94 in each group). Considering the same α =0.05, we recalculated the statistical power of the 126 obtained sample with the observed difference between groups (an absolute reduction of 11.7% and 127 relative reduction of 50%), which resulted in ~85%. 128 All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 29, 2021. ; https://doi.org/10.1101/2021.04.28.21255834 doi: medRxiv preprint There were no relevant differences in the rest of the baseline characteristics between groups, 155 including the number of patients who received dexamethasone or tocilizumab as part of in-hospital 156 medical management ( Table 1) . All participants were hypoxemic and received supplementary oxygen 157 as part of in-patient management. The median interval from symptom onset to randomization was 10 158 days (IQR, 9 to 12 days). The median interval from hospital admission to randomization was 2 days 159 (IQR, 1 to 3 days). Dexamethasone was administered to 140 participants (69 on the pyridostigmine 160 group and 71 on the placebo group). Tocilizumab was administered to 10 participants (5 on the 161 pyridostigmine group, and 5 on the placebo group). None of the participants received remdesivir 162

Thirty-three participants met the primary outcome by day 28; 11 (11.7%) in the pyridostigmine group 164 and 22 (23.4%) in the control group (HR 0.47, 95% CI 0.23-0.95, p=0.03) (Fig. 2) . As obesity status 165 differed between study groups, we performed an unplanned sensitivity analysis with a Cox 166 proportional hazards model adjusted for obesity status. We excluded 10 patients (four from the 167 pyridostigmine group and six from the control group) that had no information on obesity status (of 168 which only one had a primary outcome) for this sensitivity analysis, obtaining an adjusted HR of 0.42 169 (95% CI 0.19-0.91) for the primary outcome, 0.78 (95%CI 0.24-2.54) for IMV, and 0.32 (95%CI 0.13-170 0.77) for death. 171

IMV was initiated in 6 (6.4%) patients in the pyridostigmine group and 7 (7.5%) in the placebo group 173 (HR 0.81, 95%CI 0.27-2.42). The median duration of IMV was 15 days (IQR, 10 to 23) in the 174 pyridostigmine group and 17 days (IQR, 7 to 39) in the placebo group. The survival rate after IMV was 175 66.7% (four patients) in the pyridostigmine group and 42.9% (three patients) in the placebo group. 176

A total of 26 patients died by day 28, 7 in the pyridostigmine group and 19 in the placebo group (HR 177 0.33, 95%CI 0.14-0.81). All of the deaths in the pyridostigmine group occurred in the study center 178 All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 29, 2021. ; https://doi.org/10.1101/2021.04.28.21255834 doi: medRxiv preprint median duration of in-hospital stay after randomization (censored at day 29) was 5 days (IQR, 3 to 10 180 days) in the pyridostigmine group and 5 days (IQR, 3 to 8 days) in the placebo group. The twenty-181 eight-day hospital discharge rate was 90.4% (85 patients) in the pyridostigmine group and 75.5% (71 182 patients) in the control group (Table 2 and Fig. 3) . The use of dexamethasone was well balanced 183 between groups (69 in the pyridostigmine group and 71 in the placebo group). A higher proportion of 184 outcomes occurred among patients in the placebo group that did not use dexamethasone (35% of 185 them had an outcome vs 20% of those who did use dexamethasone). The numbers in the 186 pyridostigmine group were 8% and 13% (did not use and did use, respectively). 187

We collected and analyzed 83 AEs throughout the study. Overall, 45 (47.9%) patients of the 188 pyridostigmine group and 38 (40.4%) of the placebo group had at least one adverse drug reaction. 189

The rate and severity of AEs were similar between both groups (Supplemental Tables 1-3) . 190

Of the 188 participants, 166 (88.3%) received experimental treatment as assigned during their in-191 hospital stay; 22 (11.7%) discontinued treatment early, nine (9.5%) in the pyridostigmine group, and 192 13 (13.8%) in the placebo group. Two participants in each group discontinued trial medication due to 193 an adverse event other than the principal outcome: one patient presented nausea and one mild 194 abdominal pain in the pyridostigmine group (known adverse effects of pyridostigmine), and in the 195 placebo group one patient had pyrosis and one presented diarrhea. The remaining patients 196 discontinued trial medication after being transferred to another facility (Fig. 1) Early reports estimated mortality rates as high as 49% for hospitalized patients with severe COVID-205 19 18 . Although the in-hospital mortality rate has been declining throughout the pandemic, recent 206 studies still show rates ranging from 20 to over 40% [19] [20] [21] concerns, at the used dose of pyridostigmine, the rate of adverse events we observed was 47.9%, 233 none of them severe and it was no different from the observed in the placebo group (40.4%). The 234 reduction in mortality in patients with severe COVID-19 who received pyridostigmine may be due to an 235 immunomodulatory effect, however, its precise biological effect in this novel disease remains to be 236 studied. Different immunomodulatory strategies have been tested that have sought to selectively 237 inhibit the biological activity of certain pro-inflammatory cytokines, such as IL-6 31 ; however, the global 238 inhibition of several of them by pharmacologically stimulating the inflammatory reflex could be more 239 effective, which is the effect sought with the administration of pyridostigmine. 240

Our study has important limitations. The originally planned sample size could not be achieved. Still, a 241 significant difference was observed because of a greater than expected effect. Also, it is possible that 242 some patients requiring IMV could not receive it because of either, a pre-existing living will; last-minute 243 patient (or proxy) refusal of intubation; or, intermittently throughout the study period, hospital 244 saturation of critical-care beds 19,20 . Our outcome included starting, but not necessarily the requirement 245 of, IMV. This is reflected in the fact that the bulk of the primary outcome was due to deaths without 246 receiving IMV, most likely due to lack of critical care space. Thus, our results may not be generalizable 247 to places that do not have this problem. Importantly, we do not have a disease severity measure at 248 randomization, so groups could be imbalanced in this sense. Nonetheless, both groups should be 249 equally affected by this limitation. As a proof-of-concept, this study needs to be replicated or refuted in 250 independent clinical trials. Also, at this point, our results cannot be extrapolated to patients with less 251 severe disease, or those already receiving IMV, without prior verification in clinical trials. Finally, 252 medium-term outcomes (90 days) will be reported at a later time point. 253

The strengths of the study include that it is a double-blinded placebo-controlled multicentric 254 randomized clinical trial that evaluated an inexpensive treatment, has a positive pharmacological 255 profile, is safe, and is widely available in a generic presentation. The demographics of our study 256 All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 29, 2021. ; https://doi.org/10.1101/2021.04.28.21255834 doi: medRxiv preprint underserved population worldwide (particularly across the Americas), a population in urgent need of 258 safe, effective, life-saving, and affordable treatments for severe In conclusion, we present compelling evidence to support the use of pyridostigmine as an add-on 260 treatment to standard medical care in patients hospitalized for severe COVID-19. Our data indicate 261 that this inexpensive drug may significantly reduce mortality without imposing relevant adverse effects. 262 2 (2) 2 (2) -*For time to discharge home in patients that were transferred, the time from randomization until 275 discharge home from the hospital that they were transferred to was used. Two patients did not have 276 this information available but were discharged home alive. For them, the date of transfer was used. 277

Patients that were still in the hospital on day 28 were censored on day 29. 278 279 All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. In the case of IMV as the primary outcome, deaths without IMV were censored. In the case of death 286 as the primary outcome, IMV was not taken into account. In the case of discharge home as the 287 primary outcome, IMV, deaths, and hospital transfers were censored. 288 289 All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. 

Myasthenia gravis: Subgroup classification and therapeutic 314 strategies

Pyridostigmine Used as a Nerve Agent Pretreatment Under 316

Wartime Conditions

Acetylcholine-esterase inhibitor pyridostigmine decreases T cell overactivation in 319 patients infected by HIV

Add-on Pyridostigmine enhances 321

CD4+ T-cell recovery in HIV-1-infected immunological non-responders: A proof-of-concept 322 study

The effect of pyridostigmine on small intestinal 324 bacterial overgrowth (SIBO) and plasma inflammatory biomarkers in HIV-associated autonomic 325 neuropathies

On the analysis of 338 mortality risk factors for hospitalized COVID-19 patients: A data-driven study using the major 339 Brazilian database

Cholinergic agonists attenuate renal ischemia-reperfusion 341 injury in rats

Galantamine alleviates inflammation and other 343 obesity-associated complications in high-fat diet-fed mice

Forebrain cholinergic dysfunction and systemic 346 and brain inflammation in murine sepsis survivors

Forebrain cholinergic signaling regulates innate 349 immune responses and inflammation

This study was funded by Consejo Nacional de Ciencia y Tecnología, Mexico

All rights reserved. No reuse allowed without permission.(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.